Showing 1 - 3 results of 3 for search 'A-O. Abdallah', query time: 2.45s
Refine Results
-
1
Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up by A. Medaglia, A.D. Cohen, H.C. Lee, S. Trudel, A-O. Abdallah, N. Callander, E. Libby, L. Karlin, S. Lonial, L. Womersley, J. Baron, E. Lewis, K. Nungesser, I. Gupta, J. Opalinska
Published 2020-09-01
Article -
2
Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen... by S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia
Published 2020-09-01
Article -
3
P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA by S. Z. Usmani, M. Mielnik, Y. Koh, A. Alonso Alonso, X. Leleu, H. Quach, C.-K. Min, W. Janowski, A.-O. Abdallah, M. Garg, I. Sandhu, E. M. Ocio San Miguel, A. Oriol, P. Rodriquez-Otero, K. Ramasamy, K. Weisel, B. Besemer, M. Cavo, X. L. Zhou, M. C. Kaisermann, C. M. Bego Marques, D. Williams, F. Carreno, B. E. Kremer, I. V. Gupta, M. Hus
Published 2022-06-01
Article